A global respiratory syncytial virus (RSV) vaccine has entered late-stage clinical trials for the first time in Korea, testing its potential for commercialization. Pfizer recently received approval to initiate a Phase III clinical trial in Korea to evaluate the immunogenicity of its RSV vaccine. Moderna is applying for Japanese approval of its RSV vaccine, which was approved in the U.S. in May, and making its way into Asian countries. Among domestic biotech companies, EuBiologics has entered Phase I clinical trials in Korea.

RSV is a virus that causes pneumonia and bronchitis. The virus can affect a person of any age, but the infection rate is particularly high in infants and young children. It is the lead